Disease Detail

ID DOID:3748
Name esophagus squamous cell carcinoma
Definition An esophageal carcinoma that derives_from epithelial squamous cells located_in the esophagus.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer esophageal cancer esophageal carcinoma esophagus squamous cell carcinoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Fluorouracil + OBP-801 esophagus squamous cell carcinoma not applicable detail...
Unknown unknown Valproic acid esophagus squamous cell carcinoma not applicable detail...
Unknown unknown YM155 esophagus squamous cell carcinoma not applicable detail...
Unknown unknown Imetelstat + Radiotherapy esophagus squamous cell carcinoma not applicable detail...
Unknown unknown Camrelizumab esophagus squamous cell carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01490749 Phase I Carboplatin + Cetuximab + Everolimus + Paclitaxel Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer Completed
NCT01822613 Phase Ib/II Docetaxel + Irinotecan + Paclitaxel Alpelisib + LJM716 Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) Completed
NCT02013154 Phase I DKN-01 + Paclitaxel A Study of DKN-01 in Combination With Paclitaxel Recruiting
NCT02389751 Phase I Carboplatin Paclitaxel Ganetespib A Study of Ganetespib in Combination With Chemoradiation Active, not recruiting
NCT02559687 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) Active, not recruiting
NCT02564263 Phase III Pembrolizumab Docetaxel + Irinotecan + Paclitaxel Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Active, not recruiting
NCT02710396 Phase II Carboplatin + Pembrolizumab + Pemetrexed Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Recruiting
NCT02971956 Phase II Pembrolizumab A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer Active, not recruiting
NCT03132922 Phase I Autologous MAGE-A4 C1032 TCR-modified T cells MAGE-A4c1032T for Multi-Tumor Recruiting
NCT03143153 Phase III Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) Recruiting
NCT03165994 Phase II APX005M + Carboplatin + Paclitaxel APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers Recruiting
NCT03189719 Phase III Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) Active, not recruiting
NCT03261947 Phase II TAK-931 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Recruiting
NCT03430843 Phase III Docetaxel Paclitaxel BGB-A317 Irinotecan A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Recruiting
NCT03610711 Phase Ib/II Nivolumab + Relatlimab Nivolumab REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (REACTION) Recruiting